SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2026)
SAB Biotherapeutics (SABS) posted Other Accumulated Expenses of $340715.0 for Q1 2026, up 5.57% on a QoQ basis from $322743.0 in Q4 2025, and down 54.15% year-over-year from $743100.0 in Q1 2025.
SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $340715.0 for Q1 2026.
- Quarterly Other Accumulated Expenses fell 54.15% year-over-year to $340715.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340715.0 (down 54.15% YoY) and the FY2025 annual result came in at $322743.0, down 38.13% from the prior year.
- Other Accumulated Expenses was $340715.0 for Q1 2026 at SAB Biotherapeutics, up from $322743.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.7 million in Q3 2024 and bottomed at $64850.0 in Q2 2024.
- A 5-year average of $493985.1 and a median of $343102.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses slumped 76.29% — and 2025, when it surged 1146.51%.
- SAB Biotherapeutics' Other Accumulated Expenses stood at $513110.0 in 2022, then decreased by 6.37% to $480435.0 in 2023, then grew by 8.58% to $521639.0 in 2024, then plunged by 38.13% to $322743.0 in 2025, then rose by 5.57% to $340715.0 in 2026.
- Business Quant data shows SABS's Other Accumulated Expenses at $340715.0 in Q1 2026, $322743.0 in Q4 2025, and $649957.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 69,146.49 Bn | 69,146.20 Bn | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 475.42 Bn | 470.63 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.32 Bn | 116.08 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.80 Bn | 61.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.28 Bn | 63.28 Bn | - |
| 8 | Argenx Se | 56.67 Bn | 51.48 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.15 Bn | 38.15 Bn | - |
| 10 | SAB Biotherapeutics | 193.29 Mn | 193.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,715.00 |
| Dec 31, 2025 | 322,743.00 |
| Sep 30, 2025 | 649,957.00 |
| Jun 30, 2025 | 808,363.00 |
| Mar 31, 2025 | 743,100.00 |
| Dec 31, 2024 | 521,639.00 |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 64,850.00 |
| Mar 31, 2024 | 641,334.00 |
| Dec 31, 2023 | 480,435.00 |
| Sep 30, 2023 | 210,000.00 |
| Jun 30, 2023 | 273,521.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 513,110.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 343,102.00 |
| Mar 31, 2022 | 336,619.00 |
| Dec 31, 2021 | 283,909.00 |
| Dec 31, 2020 | 90,982.00 |